Gillanders Arbuthnot Intrinsic Value
Gillanders Arbuthnot intrinsic value. Gillanders Arbuthnot (GILLANDERS) median intrinsic value is ₹223.54 from 4 valuation models (range ₹45–₹279), vs current price ₹111.77 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with GILLANDERS DCF valuation to assess whether the stock is under or overvalued.
GILLANDERS Valuation Methods Summary — DCF, Graham Number & P/E
Gillanders Arbuthnot intrinsic value across 4 models vs current price ₹111.77 — upside/downside and value range per method. Read Gillanders Arbuthnot dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹279.43 | ₹251.49 - ₹307.37 | +150.0% | Book Value/Share: ₹122.86, P/B: 2.5x |
| Revenue Multiple Method | revenue | ₹223.54 | ₹201.19 - ₹245.89 | +100.0% | Revenue/Share: ₹207.62, P/S: 1.5x |
| EBITDA Multiple Method | earnings | ₹44.71 | ₹40.24 - ₹49.18 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 12x |
| Simple DCF (5Y) | dcf | ₹61.89 | ₹49.51 - ₹74.27 | -44.6% | CF Growth: 5.0%, Discount: 15% |
GILLANDERS Intrinsic Value vs Market Price — All Valuation Models
Gillanders Arbuthnot fair value range ₹45–₹279 vs current market price ₹111.77 across 4 valuation models. For current market price and key ratios, visit GILLANDERS share price.
GILLANDERS Intrinsic Value Analysis — Undervalued or Overvalued?
Gillanders Arbuthnot median intrinsic value ₹223.54, current price ₹111.77 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GILLANDERS?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Gillanders Arbuthnot (GILLANDERS) is ₹223.54 (median value). With the current market price of ₹111.77, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹44.71 to ₹279.43, indicating ₹44.71 - ₹279.43.
Is GILLANDERS undervalued or overvalued?
Based on our multi-method analysis, Gillanders Arbuthnot (GILLANDERS) appears to be trading below calculated value by approximately 100.0%.
GILLANDERS Financial Health — Key Ratios vs Industry Benchmarks
Gillanders Arbuthnot financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -6.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.79x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GILLANDERS Cash Flow Quality — Operating & Free Cash Flow
Gillanders Arbuthnot operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹14 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹8 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹33 Cr | ₹32 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹48 Cr | ₹48 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹69 Cr | ₹68 Cr | Positive Free Cash Flow | 8/10 |